ORCID
https://orcid.org/ 0000-0003-4956-7289
Department
Biological and Pharmaceutical Sciences
Year of Study
2
Full-time or Part-time Study
Full-time
Level
Postgraduate
Presentation Type
Oral Presentation
Supervisor
Dr Niall Burke
Supervisor
Dr Joanna Tierney
Abstract
Willow bark is considered as a disposable by-product when processing willow for biomass. Willow (Salix) is known to contain high value bioactive compounds which include salicin and its derivatives, and other phytochemicals of interest such as polyphenols and flavonoids. The plant is historically known as the primary source of salicylates to which the well-known drug aspirin is derived from. The work forms part of the Interreg project BioWILL, which is focused on integrated “Zero Waste” biorefinery utilising all fractions of willow feedstock for the production of biochemicals and renewable energy. This project aims to investigate the crude and processed bark extracts from various varieties of willow for their potential capability as beneficial antioxidants, anti-inflammatory, wound healing, skin barrier and disease arrest agents in skin health care.
There was an observed significance (pS. dasycladosand S. endeavour bark extracts at a concentration range of 0.01 to 0.0001mg/ml, with 52.2% to 87.2% gap closure, respectively, against 40.8% gap closure of the untreated control on human keratinocytes. The extracts also elucidated a positive healing effect in human dermal fibroblasts. This is a promising result for the application of both of these Salix crude extracts for skin wound healing applications. The bark extracts for S. dasyclados and S. endeavour were shown to offer desirable antioxidant effects in human keratinocytes at concentration ranges of 0.1 to 0.0001 mg/ml. The mechanisms to which these extracts offer these benefits are complex and will be further explored in this project.
Keywords:
willow bark, phytochemicals, keratinocytes, dermal fibroblasts, skin care
Start Date
14-6-2022 2:00 PM
End Date
14-6-2022 2:15 PM
Recommended Citation
Marisa, Arnold, "BioWILL - Characterising Willow Bark Bio-actives for Skin Therapies" (2022). ORBioM (Open Research BioSciences Meeting). 21.
https://sword.cit.ie/orbiom/2022/schedule/21
Included in
Biotechnology Commons, Dermatology Commons, Enzymes and Coenzymes Commons, Medicinal Chemistry and Pharmaceutics Commons, Natural Products Chemistry and Pharmacognosy Commons, Nucleic Acids, Nucleotides, and Nucleosides Commons, Pathogenic Microbiology Commons, Pharmaceutical Preparations Commons
BioWILL - Characterising Willow Bark Bio-actives for Skin Therapies
Willow bark is considered as a disposable by-product when processing willow for biomass. Willow (Salix) is known to contain high value bioactive compounds which include salicin and its derivatives, and other phytochemicals of interest such as polyphenols and flavonoids. The plant is historically known as the primary source of salicylates to which the well-known drug aspirin is derived from. The work forms part of the Interreg project BioWILL, which is focused on integrated “Zero Waste” biorefinery utilising all fractions of willow feedstock for the production of biochemicals and renewable energy. This project aims to investigate the crude and processed bark extracts from various varieties of willow for their potential capability as beneficial antioxidants, anti-inflammatory, wound healing, skin barrier and disease arrest agents in skin health care.
There was an observed significance (pS. dasycladosand S. endeavour bark extracts at a concentration range of 0.01 to 0.0001mg/ml, with 52.2% to 87.2% gap closure, respectively, against 40.8% gap closure of the untreated control on human keratinocytes. The extracts also elucidated a positive healing effect in human dermal fibroblasts. This is a promising result for the application of both of these Salix crude extracts for skin wound healing applications. The bark extracts for S. dasyclados and S. endeavour were shown to offer desirable antioxidant effects in human keratinocytes at concentration ranges of 0.1 to 0.0001 mg/ml. The mechanisms to which these extracts offer these benefits are complex and will be further explored in this project.